Private Advisor Group LLC Takes Position in Insulet Co. (NASDAQ:PODD)

Private Advisor Group LLC purchased a new stake in Insulet Co. (NASDAQ:PODDFree Report) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 1,466 shares of the medical instruments supplier’s stock, valued at approximately $468,000.

A number of other institutional investors have also recently made changes to their positions in the business. Lincoln National Corp grew its holdings in shares of Insulet by 5.7% in the first quarter. Lincoln National Corp now owns 746 shares of the medical instruments supplier’s stock valued at $238,000 after purchasing an additional 40 shares in the last quarter. Keybank National Association OH lifted its position in shares of Insulet by 2.2% during the 1st quarter. Keybank National Association OH now owns 1,907 shares of the medical instruments supplier’s stock worth $608,000 after buying an additional 41 shares during the last quarter. Banque Cantonale Vaudoise lifted its position in shares of Insulet by 1.1% during the 4th quarter. Banque Cantonale Vaudoise now owns 4,133 shares of the medical instruments supplier’s stock worth $1,217,000 after buying an additional 44 shares during the last quarter. Global Retirement Partners LLC lifted its position in shares of Insulet by 51.1% during the 1st quarter. Global Retirement Partners LLC now owns 133 shares of the medical instruments supplier’s stock worth $43,000 after buying an additional 45 shares during the last quarter. Finally, Lindbrook Capital LLC lifted its position in shares of Insulet by 78.1% during the 1st quarter. Lindbrook Capital LLC now owns 114 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 50 shares during the last quarter.

Insider Activity at Insulet

In related news, SVP Dan Manea sold 175 shares of the stock in a transaction dated Tuesday, June 20th. The shares were sold at an average price of $290.00, for a total value of $50,750.00. Following the sale, the senior vice president now directly owns 4,522 shares of the company’s stock, valued at approximately $1,311,380. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other Insulet news, Director Luciana Borio sold 500 shares of the firm’s stock in a transaction dated Monday, June 5th. The shares were sold at an average price of $283.38, for a total transaction of $141,690.00. Following the sale, the director now directly owns 2,350 shares of the company’s stock, valued at approximately $665,943. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Dan Manea sold 175 shares of the firm’s stock in a transaction dated Tuesday, June 20th. The stock was sold at an average price of $290.00, for a total transaction of $50,750.00. Following the sale, the senior vice president now directly owns 4,522 shares in the company, valued at $1,311,380. The disclosure for this sale can be found here. In the last three months, insiders have sold 2,063 shares of company stock valued at $585,161. Insiders own 0.80% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Citigroup upgraded shares of Insulet from a “neutral” rating to a “buy” rating and reduced their price objective for the stock from $273.00 to $265.00 in a research report on Monday, August 21st. Raymond James reduced their price target on shares of Insulet from $350.00 to $299.00 and set an “outperform” rating for the company in a research report on Wednesday, August 9th. Piper Sandler reduced their price target on shares of Insulet from $360.00 to $325.00 in a research report on Wednesday, August 9th. StockNews.com initiated coverage on shares of Insulet in a research report on Thursday, August 17th. They issued a “hold” rating for the company. Finally, Barclays reduced their price target on shares of Insulet from $329.00 to $257.00 and set an “equal weight” rating for the company in a research report on Thursday, August 10th. Eight investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, Insulet has a consensus rating of “Moderate Buy” and a consensus target price of $296.33.

Check Out Our Latest Report on PODD

Insulet Stock Performance

NASDAQ:PODD opened at $192.18 on Friday. The company has a quick ratio of 2.38, a current ratio of 3.34 and a debt-to-equity ratio of 2.47. Insulet Co. has a fifty-two week low of $178.55 and a fifty-two week high of $335.91. The stock has a market cap of $13.42 billion, a PE ratio of 215.93, a price-to-earnings-growth ratio of 3.10 and a beta of 0.79. The firm’s fifty day simple moving average is $252.68 and its 200-day simple moving average is $285.20.

Insulet (NASDAQ:PODDGet Free Report) last issued its quarterly earnings data on Tuesday, August 8th. The medical instruments supplier reported $0.38 EPS for the quarter, beating analysts’ consensus estimates of $0.24 by $0.14. The firm had revenue of $396.50 million for the quarter, compared to analysts’ expectations of $383.97 million. Insulet had a net margin of 4.29% and a return on equity of 22.42%. Analysts expect that Insulet Co. will post 1.64 earnings per share for the current fiscal year.

About Insulet

(Free Report)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager.

See Also

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.